Disease activity indices in systemic sclerosis: A systematic literature review

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 186-192

  Melsens, Karin ^a   De Keyser, Filip ^a   Decuman, Saskia ^a   Piette, Yves ^a   Vandecasteele, Els ^b   Smith, Vanessa ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Disease activity index; Systemic sclerosis; Validity (epidemiology)

Indexed keywords

ARTICLE; COMBINED RESPONSE INDEX FOR SYSTEMIC SCLEROSIS; CONSTRUCT VALIDITY; CONTENT VALIDITY; DISEASE ACTIVITY; DISEASE ACTIVITY INDEX; DISEASE ASSESSMENT; EUROPEAN SCLERODERMA STUDY GROUP ACTIVITY INDEX; FACE VALIDITY; FEASIBILITY STUDY; HUMAN; PRIORITY JOURNAL; RELIABILITY; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; DECISION SUPPORT SYSTEM; DISABILITY; HEALTH STATUS; HEALTH STATUS INDICATOR; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; REPRODUCIBILITY; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX;

DECISION SUPPORT TECHNIQUES; DISABILITY EVALUATION; HEALTH STATUS; HEALTH STATUS INDICATORS; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; QUALITY OF LIFE; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES;

EID: 84994475863     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (74)

1. BARSOTTI S, STAGNARO C, DELLA ROSSA A: Systemic sclerosis: a critical digest of the recent literature. Clin Exp Rheumatol 2015; 33: S3-14.
2. MEDSGER TA: Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being. Rheum Dis Clin North Am 2003; 29: 255-73.
3. FAN X, POPE J, CANADIAN SCLERODERMA RESEARCH G, BARON M: What is the relationship between disease activity, severity and damage in a large Canadian systemic sclerosis cohort? Results from the Canadian Scleroderma Research Group (CSRG). Rheumatol Int 2010; 30: 1205-10.
4. SYMMONS DP: Disease assessment indices: activity, damage and severity. Baillieres Clin Rheumatol 1995; 9: 267-85.
5. VALENTINI G, SILMAN AJ, VEALE D: Assessment of disease activity. Clin Exp Rheumatol 2003; 21: S39-S41.
6. HUDSON M, STEELE R, THE CANADIAN SCLERODERMA RESEARCH GROUP (CSRG), BARON M: Update on indices of disease activity in systemic sclerosisic sclerosis. Semin Arthritis Rheum 2007; 37: 93-8.
7. WALKER JG, STEELE RJ, SCHNITZER M et al.: The association between disease activity and duration in systemic sclerosis. J Rheumatol 2010; 37: 2299-306.
8. TUGWELL P, BOERS M, BROOKS P, SIMON L, STRAND V, IDZERDA L: OMERACT: an international initiative to improve outcome measurement in rheumatology. Trials 2007; 8:38.
9. FURST D, KHANNA D, MATUCCI-CERINIC M et al.: Systemic sclerosis-Continuing progress in developing clinical measures of response. J Rheumatol 2007; 34: 1194-200.
10. MERKEL PA, CLEMENTS PJ, REVEILLE JD et al: Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003; 30: 1630-47.
11. FURST DE: Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology (Oxford) 2008; 47: S29-S30.
12. BOERS M, BROOKS P, STRAND CV, TUGWELL P: The OMERACT filter for Outcome Measures in Rheumatology. J Rheumatol 1998; 25: 198-9.
13. SINGH JA, SOLOMON DH, DOUGADOS M et al.: Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 348-52.
14. VALENTINI G, DELLA ROSSA A, BOMBARDIERI S et al.: European multicentre study to define disease activity criteria for systemic sclerosis. II. Identification of disease activity variables and development of preliminary activity indexes. Ann Rheum Dis 2001; 60: 592-8.
15. DELLA ROSSA A, VALENTINI G, BOMBARDIERI S et al.: European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001; 60: 585-91.
16. VALENTINI G, BENCIVELLI W, BOMBARDIERI S et al.: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. III. Assessment of the construct validity of the preliminary activity criteria. Ann Rheum Dis 2003; 62: 901-3.
17. VALENTINI G, D'ANGELO S, DELLA ROSSA A, BENCIVELLI W, BOMBARDIERI S: European Scleroderma Study Group to define disease activity criteria for systemic sclerosis. IV. Assessment of skin thickening by modified Rodnan skin score. Ann Rheum Dis 2003; 62: 904-5.
18. MINIER T, NAGY Z, BALINT Z et al.: Construct validity evaluation of the European Scleroderma Study Group activity index, and investigation of possible new disease activity markers in systemic sclerosis. Rheumatology 2010; 49: 1133-45.
19. KHANNA D, BERROCAL VJ, GIANNINI EH et al.: The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in early diffuse cutaneous Systemic Sclerosis. Arthritis Rheumatol 2016; 68: 299-311.
20. KHANNA D, DISTLER O, AVOUAC J et al.: Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009; 36: 2356-61.
21. KHANNA D, LOVELL DJ, GIANNINI E et al.: Development of a provisional core set of response measures for clinical trials of systemic sclerosis. Ann Rheum Dis 2008; 67: 703-9.
22. DELLA ROSSA A, BOMBARDIERI S, VALENTINI G: Comment on: Disease activity criteria in Scleroderma. Semin Arthritis Rheum 2008; 37: 271-2.
23. HUDSON M, STEELE R, LU Y: Comment on the article "Hypocomplementemia in systemic sclerosis" by Cuomo G. et al. Reumatismo 2009; 61: 156-8.
24. SMITH V, PIETTE Y, van PRAET JT et al.: Two-year results of an open pilot study of a 2-treatment course with rituximab in patients with early systemic sclerosis with diffuse skin involvement. J Rheumatol 2013; 40: 52-7.
25. BOSELLO S, de SANTIS M, LAMA G et al.: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial. Arthritis Res Ther 2010; 12: R54.
26. VANTHUYNE M, SMITH V, ARAT S et al.: Validation of a manual ability questionnaire in patients with systemic sclerosis. Arthritis Rheum 2009; 61: 695-703.
27. MUANGCHAN C, HARDING S, KHIMDAS S et al.: Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 2012; 64: 1405-14.
28. CAPORALI R, CACCIALANZA R, BONINO C et al.: Disease-related malnutrition in outpatients with systemic sclerosis. Clin Nutr 2012; 31: 666-71.
29. MARTIN P, TEODORO WR, VELOSA AP et al.: Abnormal collagen V deposition in dermis correlates with skin thickening and disease activity in systemic sclerosis. Autoimmun Rev 2012; 11: 827-35.
30. DEUSCHLE K, WEINERT K, BECKER MO, BACKHAUS M, HUSCHER D, RIEMEKASTEN G: Six-minutes walk distance as a marker for disability and complaints in patients with systemic sclerosis. Clin Exp Rheumatol 2011; 29: S53-9.
31. BONELLA F, VOLPE A, CARAMASCHI P et al.: Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28: 27-33.
32. MULLER CDS, PAIVA EDOS S, AZEVEDO VF, RADOMINSKI SC, LIMA FILHO JH: Autoantibody profile and clinical correlation in a group of patients with systemic sclerosis in southern Brazil. Rev Bras Reumatol 2011; 51: 314-8, 323-4.
33. MICHALSKA-JAKUBUS M, KOWAL-BIELECKA O, CHODOROWSKA G, BIELECKI M, KRASOWSKA D: Angiopoietins-1 and-2 are differentially expressed in the sera of patients with systemic sclerosis: high angiopoietin-2 levels are associated with greater severity and higher activity of the disease. Rheumatology (Oxford) 2011; 50: 746-55.
34. VETTORI S, MARESCA L, CUOMO G, ABBADESSA S, LEONARDO G, VALENTINI G: Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. Scand J Rheumatol 2010; 39: 485-9.
35. MINIER T, PENTEK M, BRODSZKY V et al.: Cost-of-illness of patients with systemic sclerosis in a tertiary care centre. Rheumatology (Oxford) 2010; 49: 1920-8.
36. CUOMO G, SANTORIELLO C, POLVERINO F, RUOCCO L, VALENTINI G, POLVERINO M: Impaired exercise performance in systemic sclerosis and its clinical correlations. Scand J Rheumatol 2010; 39: 330-5.
37. SLOBODIN G, AHMAD MS, ROSNER I et al.: Regulatory T cells (CD4(+)CD25(bright) FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010; 261: 77-80.
38. VACCA A, CORMIER C, PIRAS M, MATHIEU A, KAHAN A, ALLANORE Y: Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis. J Rheumatol 2009; 36: 1924-9.
39. VANTHUYNE M, SMITH V, ARAT S et al.: Validation of a manual ability questionnaire in patients with systemic sclerosis. Arthritis Rheum 2009; 61: 695-703.
40. ALLANORE Y, MEUNE C, VONK MC et al: Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis. Ann Rheum Dis 2010; 69: 218-21.
41. HANKE K, DAHNRICH C, BRUCKNER CS et al.: Diagnostic value of anti-topoisomerase I antibodies in a large monocentric cohort. Arthritis Res Ther 2009; 11: R28.
42. VOLPE A, RUZZENENTE O, CARAMASCHI P et al.: Clinical associations of anti-CENP-B and anti-Scl70 antibody levels measured by multiplexed fluorescent microsphere immunoassay in systemic sclerosis. Rheumatol Int 2009; 29: 1073-9.
43. NEVSKAYA T, BYKOVSKAIA S, LYSSUK E et al.: Circulating endothelial progenitor cells in systemic sclerosis: relation to impaired angiogenesis and cardiovascular manifestations. Clin Exp Rheumatol 2008; 26: 421-9.
44. ALLANORE Y, BATTEUX F, AVOUAC J, ASSOUS N, WEILL B, KAHAN A: Levels of circulating endothelial progenitor cells in systemic sclerosis. Clin Exp Rheumatol 2007; 25: 60-6.
45. SFRENT-CORNATEANU R, MIHAI C, BALAN S, IONESCU R, MOLDOVEANU E: The IL-6 promoter polymorphism is associated with disease activity and disability in systemic sclerosis. J Cell Mol Med 2006; 10: 955-9.
46. VOLPE A, SALVAGNO GL, LIPPI G et al.: Low levels of activated factor VII in systemic sclerosis. J Thromb Thrombolysis 2006; 22: 133-8.
47. VOLPE A, BIASI D, CARAMASCHI P et al.: Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford) 2006; 45: 314-20.
48. DANIELI E, AIRO P, BETTONI L et al.: Healthrelated quality of life measured by the Short Form 36 (SF-36) in systemic sclerosis: correlations with indexes of disease activity and severity, disability, and depressive symptoms. Clin Rheumatol 2005; 24: 48-54.
49. LA MONTAGNA G, MELI R, CRISCUOLO T, D'ANGELO S, VALENTINI G: Bioactivity of prolactin in systemic sclerosis. Clin Exp Rheumatol 2004; 22: 145-50.
50. BUDULGAN M, DILEK B, BAG SB et al.: Relationship between serum leptin level and disease activity in patients with systemic sclerosis. Clin Rheumatol 2014; 33: 335-9.
51. TOMCIK M, CEREZO LA, SKACELOVA S et al.: Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis. Ann Rheum Dis 2014; 73: A48.
52. KECK AD, FOOCHAROEN C, ROSATO E et al.: Nailfold capillary abnormalities in erectile dysfunction of systemic sclerosis: a EUSTAR group analysis. Rheumatology (Oxford) 2014; 53: 639-43.
53. GOLEMATI C, MOUTSOPOULOS H, VLACHOYIANNOPOULOS P: Psychological characteristics of systemic sclerosis patients and their correlation with major organ involvement and disease activity. Clin Exp Rheumatol 2013; 31: S37-S45.
54. DUNNE JV, KEEN KJ, van EEDEN SF: Circulating angiopoietin and Tie-2 levels in systemic sclerosis. Rheumatol Int 2013; 33: 475-84.
55. CUOMO G, ABIGNANO G, RUOCCO L, VETTORI S, VALENTINI G: [Hypocomplementemia in systemic sclerosis]. Reumatismo 2008; 60: 268-73.
56. ROSATO E, ROMANIELLO A, MAGRI D et al.: Exercise tolerance in systemic sclerosis patients without pulmonary impairment: correlation with clinical variables. Clin Exp Rheumatol 2014; 32: S103-8.
57. SAMBATARO D, SAMBATARO G, ZACCARA E et al.: Nailfold videocapillaroscopy microhaemorrhage and giant capillary counting as an accurate approach for a steady state definition of disease activity in systemic sclerosis. Arthritis Res Ther 2014; 16: 462.
58. LANTERI A, SOBANSKI V, LANGLOIS C et al.: Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity. Autoimmun Rev 2014; 13: 974-80.
59. TEDESCHINI E, PINGANI L, SIMONI E et al.: Correlation of articular involvement, skin disfigurement and unemployment with depressive symptoms in patients with systemic sclerosis: a hospital sample. Int J Rheum Dis 2014; 17: 186-94.
60. LAMBRECHT S, SMITH V, de WILDE K et al.: Growth differentiation factor 15, a marker of lung involvement in systemic sclerosis, is involved in fibrosis development but is not indispensable for fibrosis development. Arthritis Rheumatol 2014; 66: 418-27.
61. GIOVANNETTI A, MASELLI A, COLASANTI T et al.: Autoantibodies to estrogen receptor alpha in systemic sclerosis (SSc) as pathogenetic determinants and markers of progression. PLoS One 2013; 8: e74332.
62. SOYDINC S, TURKBEYLER IH, PEHLIVAN Y et al.: Mean platelet volume seems to be a valuable marker in patients with systemic sclerosis. Inflammation 2014; 37: 100-6.
63. KOCA SS, AKBAS F, OZGEN M et al.: Serum galectin-3 level in systemic sclerosis. Clin Rheumatol 2014; 33: 215-20.
64. PERROT S, DIEUDE P, PEROCHEAU D, ALLANORE Y: Comparison of pain, pain burden, coping strategies, and attitudes between patients with systemic sclerosis and patients with rheumatoid arthritis: a cross-sectional study. Pain Med 2013; 14: 1776-85.
65. SARIYILDIZ MA, BATMAZ I, BUDULGAN M et al.: Sleep quality in patients with systemic sclerosis: relationship between the clinical variables, depressive symptoms, functional status, and the quality of life. Rheumatol Int 2013; 33: 1973-9.
66. PEROSA F, FAVOINO E, CUOMO G et al.: Clinical correlates of a subset of anti-CENPA antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis. Arthritis Res Ther 2013; 15: R72.
67. FAVOINO E, FAVIA IE, VETTORI S et al.: Clinical correlates of human leucocyte antigen (HLA)-G in systemic sclerosis. Clin Exp Immunol 2015; 181: 100-9.
68. YALCINKAYA Y, PEHLIVAN O, OMMA A et al.: The relationship between nailfold capillaroscopic assessment and telangiectasia score with severity of peripheral vascular involvement in systemic sclerosis. Clin Exp Rheumatol 2015; 33: S92-7.
69. FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum 1993; 36: 729-40.
70. BOERS M, TUGWELL P: OMERACT conference questionnaire results. OMERACT Committee. J Rheumatol 1993; 20: 552-4.
71. KHANNA D: A standardized core set for systemic sclerosis clinical trials. First step in development of combined response index. Rheumatology (Oxford) 2008; 47: S31-S2.
72. KHANNA D, BERROCAL V, SEIBOLD J et al.: Combined Response Index in Diffuse Systemic Sclerosis (CRISS). Which external anchors to use when developing the index? Baseline analysis. Arthritis Rheum 2012; 64: 92.
73. GLADUE H, FURST D, BERROCAL V et al.: Comparison of baseline characteristics of the combined response index for systemic sclerosis (CRISS) cohort to patients enrolled in clinical trials of diffuse systemic sclerosis. Arthritis Rheum 2012; 64: 1464.
74. POPE JE, BELLAMY N, SEIBOLD JR et al.: A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum 2001; 44: 1351-8.